Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins

J Virol Methods. 2010 Sep;168(1-2):248-50. doi: 10.1016/j.jviromet.2010.04.025. Epub 2010 May 4.

Abstract

Monoclonal antibodies (MAbs) were developed against soluble Ebola virus (EBOV) envelope glycoprotein (GP) for the study of the diversity of EBOV envelope and development of diagnostic reagents. Of the three anti-EBOV GP mouse MAbs produced, MAb 15H10 recognized all human EBOV GP species tested (Zaire, Sudan, Ivory Coast), and as well as reacted with the Reston nonhuman primate EBOV GPs. A second MAb, 6D11 recognized EBOV GP species of Sudan and Sudan-Gulu. The third MAb, 17A3, was reported originally in the same article to be EBOV GP specific has now been found to be specific for bovine and human alpha-2-macroglobulin (alpha-2M) proteins which were contaminants in the Ebola envelope protein preparation. Thus, while MAbs 15H10 and 6D11 are indeed EBOV GP specific, MAb 17A3 is an alpha-2-macroglobulin MAb.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Viral / immunology*
  • Ebolavirus / immunology*
  • Hemorrhagic Fever, Ebola / diagnosis*
  • Hemorrhagic Fever, Ebola / virology
  • Humans
  • Mice
  • Sensitivity and Specificity
  • Viral Envelope Proteins / immunology
  • alpha-Macroglobulins / immunology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Viral Envelope Proteins
  • alpha-Macroglobulins
  • envelope glycoprotein, Ebola virus